See more : DNAPrint Genomics, Inc. (DNAG) Income Statement Analysis – Financial Results
Complete financial analysis of Dong-A ST Co., Ltd. (170900.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dong-A ST Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Mydas Real Estate Investments Ltd (MYDS.TA) Income Statement Analysis – Financial Results
- Doré Copper Mining Corp. (DRCMF) Income Statement Analysis – Financial Results
- Tucows Inc. (TCX) Income Statement Analysis – Financial Results
- CompX International Inc. (CIX) Income Statement Analysis – Financial Results
- Korporacja KGL S.A. (KGL.WA) Income Statement Analysis – Financial Results
Dong-A ST Co., Ltd. (170900.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.donga-st.com
About Dong-A ST Co., Ltd.
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, including Closerin for active pulmonary and extra-pulmonary tuberculosis; Dulastin and Leucostim for neutropenia in patients receiving myelosuppressive chemotherapy; Eporon for anemia associated with chronic renal failure; Gemcit for non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin for infertility and annovulation; Growtropin II for growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel for breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone for use in functional dyspepsia treatment; Stillen for the treatment of gastritis; Suganon for diabetes treatment; Terizidone for active pulmonary and extra-pulmonary tuberculosis; and Zydena for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high technology medical devices, custom made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 663.98B | 635.39B | 593.23B | 586.73B | 612.31B | 567.43B | 555.03B | 560.54B | 581.00B | 578.64B | 500.97B |
| Cost of Revenue | 341.77B | 320.00B | 299.35B | 302.39B | 300.32B | 274.14B | 275.08B | 283.77B | 279.07B | 268.51B | 236.05B |
| Gross Profit | 322.21B | 315.39B | 293.88B | 284.34B | 311.99B | 293.30B | 279.95B | 276.77B | 301.92B | 310.13B | 264.92B |
| Gross Profit Ratio | 48.53% | 49.64% | 49.54% | 48.46% | 50.95% | 51.69% | 50.44% | 49.38% | 51.97% | 53.60% | 52.88% |
| Research & Development | 105.49B | 88.18B | 82.64B | 76.15B | 74.12B | 74.01B | 78.70B | 69.54B | 58.89B | 63.60B | 53.14B |
| General & Administrative | 49.48B | 39.86B | 41.24B | 35.24B | 40.71B | 43.67B | 54.76B | 63.07B | 64.87B | 68.46B | 66.24B |
| Selling & Marketing | 45.72B | 61.12B | 55.82B | 43.17B | 44.95B | 46.92B | 37.81B | 35.75B | 36.12B | 40.55B | 42.15B |
| SG&A | 201.47B | 100.97B | 97.06B | 78.40B | 85.66B | 90.59B | 92.57B | 98.82B | 100.99B | 109.01B | 108.39B |
| Other Expenses | 0.00 | 109.07B | 98.56B | 95.79B | 95.65B | -16.57B | 2.63B | -11.90B | 3.64B | 3.17B | -16.80B |
| Operating Expenses | 306.96B | 298.22B | 278.26B | 250.35B | 255.43B | 253.86B | 256.08B | 261.92B | 246.54B | 260.76B | 225.13B |
| Cost & Expenses | 652.80B | 618.22B | 577.61B | 552.73B | 555.75B | 528.00B | 531.16B | 545.69B | 525.61B | 529.27B | 461.18B |
| Interest Income | 9.19B | 2.76B | 1.17B | 4.06B | 5.91B | 4.56B | 2.21B | 2.11B | 1.94B | 2.72B | 2.46B |
| Interest Expense | 12.72B | 8.11B | 5.62B | 5.19B | 7.56B | 6.85B | 8.57B | 11.91B | 15.36B | 14.16B | 11.75B |
| Depreciation & Amortization | 26.34B | 20.85B | 19.95B | 19.97B | 20.49B | 20.04B | 21.72B | 21.08B | 23.98B | 24.92B | 20.40B |
| EBITDA | 46.66B | 49.40B | 35.51B | 58.85B | 77.05B | 59.47B | 44.66B | 33.66B | 77.84B | 74.29B | 49.07B |
| EBITDA Ratio | 7.03% | 6.51% | 6.98% | 8.30% | 19.84% | 8.14% | 4.40% | 6.25% | 16.11% | 14.51% | 9.48% |
| Operating Income | 11.18B | 16.67B | 21.43B | 33.99B | 100.99B | 39.44B | 23.87B | 14.84B | 55.39B | 49.37B | 39.79B |
| Operating Income Ratio | 1.68% | 2.62% | 3.61% | 5.79% | 16.49% | 6.95% | 4.30% | 2.65% | 9.53% | 8.53% | 7.94% |
| Total Other Income/Expenses | -3.59B | -8.52B | -3.53B | -706.37M | 24.86B | -23.36B | -32.22B | -14.21B | 1.99B | -3.64B | -22.87B |
| Income Before Tax | 7.59B | 17.52B | 12.09B | 33.29B | 89.00B | 16.07B | -8.35B | 628.45M | 63.89B | 45.73B | 16.92B |
| Income Before Tax Ratio | 1.14% | 2.76% | 2.04% | 5.67% | 14.54% | 2.83% | -1.50% | 0.11% | 11.00% | 7.90% | 3.38% |
| Income Tax Expense | 3.98B | 4.74B | -726.57M | 6.18B | 18.09B | 8.06B | -2.95B | -2.01B | 15.32B | 8.18B | 82.63B |
| Net Income | 11.12B | 13.55B | 12.82B | 27.10B | 70.91B | 8.01B | -5.40B | 10.63B | 48.56B | 37.41B | -65.72B |
| Net Income Ratio | 1.68% | 2.13% | 2.16% | 4.62% | 11.58% | 1.41% | -0.97% | 1.90% | 8.36% | 6.47% | -13.12% |
| EPS | 1.47K | 1.54K | 1.46K | 3.09K | 8.08K | 930.39 | -626.47 | 1.24K | 6.07K | 4.87K | -8.82K |
| EPS Diluted | 1.25K | 1.40K | 1.41K | 3.09K | 8.08K | 930.39 | -626.47 | 1.24K | 6.07K | 4.58K | -8.82K |
| Weighted Avg Shares Out | 8.66M | 8.78M | 8.78M | 8.78M | 8.78M | 8.61M | 8.61M | 8.55M | 8.00M | 7.68M | 7.45M |
| Weighted Avg Shares Out (Dil) | 10.18M | 10.18M | 9.28M | 8.78M | 8.78M | 8.61M | 8.61M | 8.55M | 8.00M | 8.17M | 7.45M |
Source: https://incomestatements.info
Category: Stock Reports